Join former physician, now CEO of immuno-diagnostics company, Adam M Hill as he speaks with leading experts and peers from across the healthcare and life science industry to discuss the opportunities and challenges they’re facing and what drives them to work towards delivering scalable improvements in health outcomes.
Dr Parag Mallick
Adam talks to Dr Parag Mallick from Stanford University where he is a Professor. Having originally trained as an engineer biochemist, Parag's research is diverse and spans computational and experimental systems biology, cancer biology, and nanotechnology.
Parag talks about the diverse applications of proteomics and the value of bringing together different perspectives and disciplines to tackle challenging problems like biomarker analysis and personalised medicine. He also talks about the importance of and future opportunity for bioinformatics and shares his thoughts on the broader recognition of early detection that started to gain momentum in immuno-oncology but has now expanded to other treatment modalities.
Professor Ola Winqvist
Adam talks to Ola Winqvist, Professor of Cellular Immunotherapy at the Karolinska Institute and Chief Physician of Clinical Immunology at the Karolinska University Hospital.
Ola gives Adam a primer on the immune system, how it responds to disease and infection, and particularly, the role of autoantibodies as biomarkers or targets for some therapies. Ola also talks about the changes he has seen in in the field of immunology over the last thirty years and he shares his thoughts on how Sweden has managed the pandemic.
Professor Chris Molloy
Adam talks to Professor Chris Molloy, CEO of the UK's Medicines Discovery Catapult, the National Research Technology Facility supporting the sector by industrialising and driving the adoption of new approaches to discovering medicines.
Most recently, Chris has been responsible for establishing and running the Lighthouse Labs, the biggest diagnostic lab in British history. Developed in partnership with AstraZeneca and GSK, these labs provide diagnostics infrastructure, which have the capability to test tens of thousands of patient samples each day for Coronavirus.
Chris talks about the herculean task he and his team had in setting up the LightHouse Labs, what he is most proud of and with the lab infrastructure now in place, what are the opportunities to test, trace, and better stratify patients into various forms of therapies in the United Kingdom.
Dr Richard Roope
Adam talks to Dr Richard Roope, a General Practitioner with a special interest in cancer management and Senior Clinical Advisor (for Prevention and Early Diagnosis) at Cancer Research UK. As we find ourselves in the middle of a pandemic, which has put extreme pressure on cancer services globally, Richard discusses our biggest challenge when it comes to cancer management. He also talks about why it is we have seen less referrals for all cancers and lung cancer in particular, and how we can reach out to the missing patients.
Dr Melanie Lee
Adam talks to Dr Melanie Lee, Chief Executive of British life science medical research charity, LifeArc.
Melanie talks about her journey and how she made the leap from academia to industry, the people that inspired her along her journey and what change she has seen over the years in attitudes towards the early detection of disease. Melanie shares her views on what the diagnostics industry could be doing to support the NHS in managing the backlog of disease as a result of the pandemic. She also talks about what projects she is most excited about at LifeArc, and what we can expect to see more of over the next 12 months.
Professor Gino Martini
Adam talks to Professor Gino Martini, Chief Scientific Officer for the Royal Pharmaceutical Society, the body that supports pharmacists across the UK as well as championing pharmacy across media and government and leading the way in medicines information.
Professor Martini talks about his career, the effect the pandemic will have on the speed of drug development and what the future of community pharmacy will look like. He also talks about how the pharmaceutical industry is embracing precision medicine and evolving with the introduction of various diagnostic tools that give us the opportunity to detect earlier and stratify patients better.